Innate Pharma announces data presentations at upcoming scientific meetings

-- Updated long term follow-up data and new data from cohort expansion in the Phase I of IPH4102 in advanced CTCL at the EORTC CLTF 2018 Meeting -- Updated data from Phase I/II fully-enrolled study of monalizumab in combination with cetuximab in SCCHN at the ESMO 2018 congress

Marseille, France, September 10, 2018

Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announced that updated data from ongoing clinical trials evaluating first-in-class antibody, IPH4102, and lead asset, monalizumab, partnered with AstraZeneca/MedImmune, will be presented at the EORTC CLTF[*] 2018 Meeting in St Gallen, Switzerland, September 27-29, 2018 and at the ESMO[**] 2018 Congress in Munich, Germany, October 19-23, 2018, respectively. Moreover, Eric Vivier, Chief Scientific Officer, is invited to the ESMO Congress as speaker in the Early detection of cancer using minimally invasive biomarkers Special Symposium.

EORTC CLTF 2018 for IPH4102:

-- Title: IPH4102 in relapsed/refractory cutaneous T cell lymphoma (CTCL): Results of the first-in-human multicenter phase 1 study -- Date and time: September 29, 2018, 8:30 - 9:45 -- Presentation number: 078 -- Session: Oral presentation, Session 8 / Treatment and clinical cases -- Presenter: Martine Bagot, Principal Investigator and Head of the Dermatology Department at the Saint-Louis Hospital, Paris, France -- Location: Olma Messen Hall 9.2, St-Gallen, Switzerland

ESMO 2018 Congress for monalizumab:

-- Title: Results of a Phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) -- Date and time: October 20, 2018, 15:00 -- Presentation number: 1049PD -- Session: Poster Discussion session - Head and neck -- Presenter: Jérôme Fayette, Medical Oncologist at the Centre Léon Bérard Lyon, France -- Location: Hall B3 - Room 23, ICM München, Munich, Germany -- Title: Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with Durvalumab plus Monalizumab (anti-NKG2A) -- Date & time: October 20, 2018, 12:30 -- Presentation number: 1194P -- Session: Poster Display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research (ID 259) -- Presenter: Jennifer R. Diamond, Associate Professor, Division of Medical Oncology at the Colorado University, Denver, US -- Location: Hall A3, Poster Area Networking Hub, ICM München, Munich, Germany -- Title: Changes in the innate immune system as early events in cancer -- Date & time: October 22, 2018, 15:05 - 15:25 -- Session: Special Symposium Early detection of cancer using minimally invasive biomarkers -- Presenter: Eric Vivier, Chief Scientific Officer of Innate Pharma, Marseille, France -- Location: Hall A1 - Room 17, ICM München, Munich, Germany

The full list of events Innate Pharma is participating in is available and regularly updated on the Company's website in the " Events " section.

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the body's own immune system.

Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells.

The Company's broad pipeline includes several first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs.

Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi. Innate Pharma is building the foundations to become a fully-integrated biopharmaceutical company.

Based in Marseille, France, Innate Pharma has more than 180 employees and is listed on Euronext Paris.

Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

ISIN code FR0010331421 Ticker code IPH LEI 9695002Y8420ZB8HJE29

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website ( www.amf-france.org ) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors International Media Innate Pharma Consilium Strategic Communications Markus Metzger / Danielle Spangler / Mary-Jane Elliott / Jessica Hodgson Jérôme Marino Tel.: +33 (0)4 30 30 30 30 Tel.: +44 (0)20 3709 5700 investors@innate-pharma.com InnatePharma@consilium-comms.com French Media ATCG Press Marie Puvieux Mob: +33 (0)6 10 54 36 72 presse@atcg-partners.com

[*] European Organisation for Research and Treatment of Cancer and Cutaneous Lymphoma Task Force

[**] European Society for Medical Oncology

Attachment

-- PR in English.pdf